JP2014518883A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518883A5
JP2014518883A5 JP2014512833A JP2014512833A JP2014518883A5 JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5 JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5
Authority
JP
Japan
Prior art keywords
tl1a
monoclonal antibody
clone
agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014512833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/028926 external-priority patent/WO2012161856A1/en
Publication of JP2014518883A publication Critical patent/JP2014518883A/ja
Publication of JP2014518883A5 publication Critical patent/JP2014518883A5/ja
Withdrawn legal-status Critical Current

Links

JP2014512833A 2011-05-20 2012-03-13 T細胞媒介疾病の病態を改善させるためのtl1a−dr3相互作用の遮断及びその抗体 Withdrawn JP2014518883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488671P 2011-05-20 2011-05-20
US61/488,671 2011-05-20
PCT/US2012/028926 WO2012161856A1 (en) 2011-05-20 2012-03-13 Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof

Publications (2)

Publication Number Publication Date
JP2014518883A JP2014518883A (ja) 2014-08-07
JP2014518883A5 true JP2014518883A5 (enExample) 2015-03-19

Family

ID=47217582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512833A Withdrawn JP2014518883A (ja) 2011-05-20 2012-03-13 T細胞媒介疾病の病態を改善させるためのtl1a−dr3相互作用の遮断及びその抗体

Country Status (8)

Country Link
US (1) US9068003B2 (enExample)
EP (1) EP2709664A4 (enExample)
JP (1) JP2014518883A (enExample)
KR (1) KR20140104344A (enExample)
AU (1) AU2012259312A1 (enExample)
CA (1) CA2836898A1 (enExample)
MX (1) MX2013013329A (enExample)
WO (1) WO2012161856A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2428321T3 (es) * 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
AU2012315474B2 (en) 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
JP2016503818A (ja) * 2013-01-02 2016-02-08 グレンマーク ファーマシューティカルズ, エセ.アー. Tl1aと結合する抗体およびその使用
EP2943253B1 (en) 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
JP6482533B2 (ja) * 2013-05-17 2019-03-13 セダーズ−シナイ メディカル センター クローン病に関連するtnfsf15及びdcr3の変異体
WO2014186665A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
EP4105236A1 (en) * 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
MX2016002879A (es) * 2013-09-06 2016-08-17 Cedars Sinai Medical Center Sistemas, dispositivos y metodos para la terapia anti-tl1a.
AU2014348676B2 (en) * 2013-11-13 2020-06-18 Bristol-Myers Squibb Company Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
US10308703B2 (en) 2014-04-28 2019-06-04 The National Institute For Biotechnology I Variants of DR3 and use thereof
CN108697659A (zh) 2015-08-21 2018-10-23 费城儿童医院 用于治疗和诊断自身免疫性疾病的组合使用的组合物和方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) * 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2017201461A1 (en) 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
CN110121509B (zh) * 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2020113116A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
PH12022550978A1 (en) 2019-10-24 2023-10-09 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
BR112022009934A2 (pt) * 2019-11-22 2022-08-09 Univ New York State Res Found Método para prevenir ou tratar diabetes tipo 1, e, composição compreendendo lipossomas
CN119256009A (zh) * 2022-06-17 2025-01-03 塞莱克辛有限公司 与人dr3特异性结合的抗体及其用途
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN116514983B (zh) * 2023-06-02 2025-05-23 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用
AU2024324300A1 (en) 2023-08-11 2026-02-12 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
WO2025076081A1 (en) 2023-10-03 2025-04-10 Absci Corporation Tl1a associated antibody compositions and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE140482T1 (de) 1992-04-28 1996-08-15 Univ Yale Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
WO1997018312A1 (en) 1995-11-14 1997-05-22 Vimrx Holdings, Ltd. Chimeric oligomers having an rna-cleavage activity
KR0161881B1 (ko) 1995-12-05 1999-02-01 문정환 메모리의 데이타 읽기회로
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
WO1998058058A1 (en) 1997-06-19 1998-12-23 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes with extended cleavage rule
US6300483B1 (en) 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
ES2428321T3 (es) * 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
WO2006127900A2 (en) * 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
AU2006284922B2 (en) * 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
UA104132C2 (en) * 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a

Similar Documents

Publication Publication Date Title
JP2014518883A5 (enExample)
Müller et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
JP2018121657A5 (enExample)
US10358493B2 (en) Bispecific format suitable for use in high-through-put screening
Igawa et al. Reduced elimination of IgG antibodies by engineering the variable region
US11286312B2 (en) Multispecific antibodies
JP2015214563A5 (enExample)
JP2017114866A5 (enExample)
JP2012012402A5 (enExample)
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
JP2012501669A5 (enExample)
JP2012501670A5 (enExample)
JP2012143232A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2013539369A5 (enExample)
JP2011523550A5 (enExample)
RU2016123839A (ru) Новые модуляторы и способы их применения
JP2017532005A5 (enExample)
JP2020501532A5 (enExample)
RU2017134909A (ru) Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения
JP2018502572A5 (enExample)
JP2017529067A5 (enExample)
JP2018516853A5 (enExample)
TWI797124B (zh) 抗干擾素-γ之抗體及其應用
JP2010533498A5 (enExample)